Let's Build Better Cells Together We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, …

337 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

673 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

97 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Biomade Peptides We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

305 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Guiding clinicians towards personalized treatment and enhancing quality of life for patients Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.

47 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

279 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

127 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing best-in-class NNMT inhibitors with a dual therapeutic effect to benefit patients with metabolic syndrome Cantoni Therapeutics is a biopharmaceutical spinout company from the University of Leiden (NL) developing best-in-class inhibitors of a single enzyme with a dual therapeutic effect to benefit patients with metabolic syndrome.

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

HP Health Solutions Life Sciences, Molecular Assays, Biotechnology, diagnostics, and corporate incubation

270 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

430 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

95 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

227 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

First in class small molecules pushing cancer cells to burn out BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer

44 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active …

172 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

134 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

544 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing deuterated BEST in CLASS MET kinase Inhibitor DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2. Drug Development, Deuterated small molecules, and MET kinase inhibitor

55 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences

218 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers.

57 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Innovation for your health and well-being. Pharmaceutical company, R&D oriented dedicated to the development and marketing of senolytic compounds, food supplements and drugs against aging, age-related degenerative diseases and cancer.

140 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

51 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology

46 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

135 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nanoparticle-Based Radiopharmaceuticals for Targeted Radiation Delivery to Cancer Cells aKen Medical is a biotechnology company that encapsulates highly potent radioactive materials within stable nanoparticles serving as "guided missiles" that deliver targeted radiation straight to tumors while protecting healthy tissue. Our universal nanoparticle platform is designed to address a wide range of cancers, enabling real-time monitoring and advancing a theranostic approach that paves the way for precision medicine. Radiopharmaceuticals, Targeted therapy, Theranostics, Radiation Therapy, Alphatherapy, Nanotechnology, Cancer Therapy, Biotechnology, Radiotherapy, and Precision Medecine

65 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precision Radiotherapy From Within BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose. radiotherapy, nuclear medicine, oncology, and medical devices

83 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

421 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

419 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

257 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

363 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

208 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

728 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

491 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

81 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Aureus Sciences focuses on providing solutions to the needs of pharmaceutical and biotech companies to leverage information and knowledge as a decision making tool and to increase the speed and efficiency of their drug discovery and development process. Over the course of 10 years and with a significant investment, the Company has developed a unique Knowledge Production Platform which analyzes, indexes and organizes critical chemical and bioactivity information into databases. Using this platform the Company provides best-in-class, scientific databases and associated software applications for use by researcher involved in the drug discovery and development process.The company's range of products includes …

97 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

213 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

613 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

602 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ikena merged with ImageneBio on in July 2025. Please visit https://inmagenebio.com/ for more information. Ikena merged with ImageneBio in July 2025. Please visit https://inmagenebio.com/ for more information. Targeted Oncology, cancer therapeutics development, small molecule drug design, cancer biology, and translational science and biomarkers

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation in Marine-Derived Oncology Therapies Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

573 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

132 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Enabling Success Sygnature Discovery, headquartered in Nottingham (UK), is a world-leading contract research organization for drug discovery. Based in the UK (Nottingham, Alderley Park, Macclesfield, Glasgow) and Canada (Montreal, Laval, Quebec) and with a staff of over 1,000, including over 900 scientists, Sygnature Discovery partners with the global pharmaceutical industry, biotechs and NfP organizations wishing to outsource part of their R&D work. Since 2004, Sygnature Discovery has delivered more than 56 new preclinical compounds, 29 clinical compounds and 1 registered, thanks to the talents of its world-class scientists, who are named on more than 500 patents. The services offered to …

51 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

182 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

84 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing Innovative Cell Therapies Against Cancer Celyad Oncology is a biotechnology company focused on the discovery and development of tecnhlologies and platform for chimeric antigen receptor T cell (CAR T) therapies. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Immuno-Oncology, Cancer, Immnotherapy, shRNA multiplex, and CAR T-cells

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology